Cancer Letters
Volume 230, Issue 1 , Pages 33-46 , 8 December 2005

Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer

  • Hisashi Nakamura

      Affiliations

    • Department of Surgery, Kurume University School of Medicine, 67 Asahi-Machi, Kurume 830-0011, Japan
    • Research Center for Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University School of Medicine, Kurume 830-0011, Japan
    • ,
  • Shinzo Takamori

      Affiliations

    • Department of Surgery, Kurume University School of Medicine, 67 Asahi-Machi, Kurume 830-0011, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 942 31 7566; fax: +81 942 34 0709.
    • ,
  • Teruhiko Fujii

      Affiliations

    • Research Center for Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University School of Medicine, Kurume 830-0011, Japan
    • ,
  • Mayumi Ono

      Affiliations

    • Department of Medical Biochemistry, Graduate School of Medical Sciences, Kyushu University School of Medicine, Fukuoka 812-8582, Japan
    • ,
  • Hideaki Yamana

      Affiliations

    • Research Center for Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University School of Medicine, Kurume 830-0011, Japan
    • ,
  • Michihiko Kuwano

      Affiliations

    • Research Center for Innovative Cancer Therapy of the 21st Century COE Program for Medical Science, Kurume University School of Medicine, Kurume 830-0011, Japan
    • ,
  • Kazuo Shirouzu

      Affiliations

    • Department of Surgery, Kurume University School of Medicine, 67 Asahi-Machi, Kurume 830-0011, Japan

Received 21 September 2004 ,Revised 26 November 2004 ,Accepted 15 December 2004.

References 

  1. Mendlsohn J, Baserga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000;19:6550–6565
  2. de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol. Med. 2002;8:19–26
  3. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Ther. 1999;82:241–250
  4. Olayioye MA, Neve RM, Lane HA. The ErbB signaling network: receptor heterodimerization in development and cancer. Eur. Mol. Biol. Org. J. 2000;19:3159–3167
  5. Salomon DS, Brndt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 1995;19:183–232
  6. Arteaga CL. Epidermal growth factor receptor dependence in human tumors: more than just expression. Oncologist. 2002;7:31–39
  7. Khazaie K, Schirrmacher V, Lichtner RB. EGFR receptor in neoplasia and metastasis. Cancer Metastasis Rev. 1993;12:255–274
  8. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs. 2000;60:15–23
  9. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. Eur. Mol. Biol. Org. J. 1997;16:1647–1655
  10. Karunagaran D, Tzahar E, Beerli RR. ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. Eur. Mol. Biol. Org. J. 1996;15:254–264
  11. Spencer KS, Graus-Porta D, Leng J. ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases. J. Cell Biol. 2000;148:385–397
  12. Sainsbury JR, Farndon JR, Needham GK, Malcolm AJ, Harris AL. Epidermal-growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987;1:1398–1402
  13. Brabender J, Danenberg KD, Metzger R, Schncider PM, Park J, Salonga D, et al. Epidermal growth factor receptors and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin. Cancer Res. 2001;7:1850–1855
  14. Veale D, Kerr N, Gibson GJ, Kelly PJ, Harris AL. The relationship of quantitive epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br. J. Cancer. 1993;68:162–165
  15. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 2001;7:1958–1970
  16. Baselga J, Averbuch SD. ZD1839 (‘Iressa’) as an anticancer agent. Drugs. 2000;60:33–40
  17. Gibbs JB. Anticancer drug targets: growth factors and growth factor signaling. J. Clin. Invest. 2000;105:9–13
  18. Noonberg SB, Benz CC. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents. Drugs. 2000;59:753–767
  19. Wakeling AE, Barker AJ, Davies DH, Brown DS, Green LR, Cartidge SA, et al. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines. Breast Cancer Res. Treat. 1996;38:67–73
  20. Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 2000;6:2053–2063
  21. Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Caccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 2001;7:1459–1465
  22. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, et al. ZD1839 (Irresa): an orally active inhibitors of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002;62:5749–5754
  23. Sirotnak FM, Zakowski MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), a inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 2000;6:4885–4892
  24. Nishiwaki Y, Yansteenkiste J, Kudoh S. A multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the IDEAL 1 trial). J. Clin. Oncol. 2003;21:2237–2241
  25. Kris M, Natale RB, Herbst R. A phase II trial of ZD1839 (‘Iressa’) in advanced non-small cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2). Proc. Am. Soc. Clin. Oncol. 2002;21:292
  26. Baselga J. Targeting the epidermal growth factor receptor-tyrosine kinase inhibitors: small molecules, big hopes. J. Clin. Oncol. 2002;20:2217–2219
  27. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 2003;21:2237–2246
  28. Shepard HM, Lewis GD, Sarup JC. Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic. J. Clin. Immunol. 1991;11:117–127
  29. Colomer R, Lupu R, Bacus SS, Gelmann EP. ErbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with ErbB-2 oncogene amplification. Br. J. Cancer. 1994;70:819–825
  30. Liu X, Pogo BG. Inhibition of ErbB-2-positive breast cancer cell growth by ErbB-2 antisense oligonucleotides. Antisense Nucleic Acid Drug Dev. 1996;6:9–16
  31. Roh H, Pippin J, Drebin JA. Down-relgulation of HER2/neu expression induces apoptosis in human cancer cells that overexpress HER2/neu. Cancer Res. 2000;60:560–565
  32. Baselga J, Tripathy D, Mendelsohn J. Phasa II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol. 1996;14:737–744
  33. Pegram MD, Lipton A, Hayes DF. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 1998;16:2659–2671
  34. Tamura T. Moleclular target-based cancer therapy: epidermal growth factor receptor inhibitors. Jpn. J. Surg. 2002;2:233–236
  35. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 (‘Iressa’) inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res. 2001;61:7184–7188
  36. Moulder SL, Yakes FM, Muthuswamy SK, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Irresa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res. 2001;61:8887–8895
  37. Normanno N, Campiglio M, De Luca A, Somenzi G, Maiello M, Ciardiello F, et al. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth. Ann. Oncol. 2002;13:65–72
  38. Anido J, Albanell J, Rojo F, Codony-Servat J, Arribas J, Baselga J. Inhibition by ZD1839 (Iressa) of epidermal growth factor (EGF) and heregulin induced signaling pathways in human breast cancer cells. Proc. Am. Soc. Clin. Oncol. 2001;20:1712A
  39. Harris AL, Nicholson S, Sainsbury JR, Farndon J, Wright C. Epidermal growth factor receptors in breast cancer: association with early relapse and death, poor response to hormones and interactions with neu. J. Steroid Biochem. 1989;34:123–131
  40. Osaki A, Toi M, Yamada H. Prognostic significance of co-expression of c-ErbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. Am. J. Surg. 1992;164:323–326
  41. Harlozninska A, Bar JK, Wenderski R, Bebenek M. Relationship between c-ErbB-2 oncoprotein, epidermal growth factor receptor, and estrogen receptor expression in patients with ductal breast carcinoma. Association with tumor phenotypes. In Vivo. 1996;10:217–222
  42. Ono M, Hirata A, Kometani T, Miyagawa M, Ueda S, Kinoshita H, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation. Mol. Cancer Ther. 2004;3:465–472
  43. Anido J, Matar P, Albanell J, Marta G, Rojo F, Arribas J, et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin. Cancer Res. 2003;9:1274–1283
  44. Aderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without ErbB2 overexpression. Int. J. Cancer. 2001;94:774–782
  45. Ye D, Mendelsohn J, Fan Z. Augmentation of a humanized anti-HER2 monoclonal antibody 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor monoclonal antibody C225. Oncogene. 1999;18:731–738
  46. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004;350:2129–2139
  47. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–1500
  48. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, et al. Lung cancer: intragenic ERBB2 kinase mutations in tumors. Nature. 2004;431:525–526
  49. Suzuki T, Nakagawa T, Endo H, Mitsudomi T, Masuda A, Yatabe Y, et al. The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 (‘Iressa’) is not related to the expression of EGFR or HER-2 or to K-ras gene status. Lung Cancer. 2003;42:35–41
  50. Janmaat ML, Kruyt FAE, Rodriguez JA, Giaccone G. Response to epidermal growth factor receptor inhibits in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin. Cancer Res. 2003;9:2316–2326

☆ Iressa is a trademark of the AstraZeneca group of companies.

PII: S0304-3835(04)00995-4

doi: 10.1016/j.canlet.2004.12.020

Cancer Letters
Volume 230, Issue 1 , Pages 33-46 , 8 December 2005

Article Tools

* Image Usage & Resolution